Several Key Catalysts Lay Ahead For Gilead Sciences In The Next Year

By: via Benzinga
Stifel Nicolaus has started coverage on Gilead Sciences, Inc. (NASDAQ: GILD) with a Buy rating and $100 target price on improving HCV ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.